How to buy Xenetic Biosciences stock (XBIO)

Xenetic Biosciences is a biotechnology business based in the US. Xenetic Biosciences shares (XBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.04 – a decrease of 5.83% over the previous week. Xenetic Biosciences employs 4 staff and has a trailing 12-month revenue of around $2.5 million.

Our top picks for where to buy Xenetic Biosciences stock

Buy Xenetic Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Xenetic Biosciences stock price (NASDAQ: XBIO)

Use our graph to track the performance of XBIO stocks over time.

Xenetic Biosciences shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$4.04
52-week range	$2.78 - $5.20
50-day moving average more info button	$4.01
200-day moving average more info button	$4.00
Wall St. target price	$40.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.66

Is it a good time to buy Xenetic Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xenetic Biosciences price performance over time

Historical closes compared with the close of $4.15 from 2024-12-24

1 week (2024-12-20)	-3.26%
1 month (2024-11-27)	-1.19%
3 months (2024-09-27)	8.92%
6 months (2024-06-27)	4.15

1 year (2023-12-27)	16.57%
2 years (2022-12-27)	43.10%
3 years (2021-12-27)	14.6
5 years (2019-12-27)	14.3

Xenetic Biosciences financials

Revenue TTM	$2.5 million
Gross profit TTM	$1.2 million
Return on assets TTM	-28.74%
Return on equity TTM	-48.61%
Profit margin	-186.33%
Book value	$6.36
Market Capitalization more info button	$6.4 million

TTM: trailing 12 months

Xenetic Biosciences share dividends

We're not expecting Xenetic Biosciences to pay a dividend over the next 12 months.

Have Xenetic Biosciences's shares ever split?

Xenetic Biosciences's shares were split on a 1:10 basis on 14 May 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Xenetic Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Xenetic Biosciences shares which in turn could have impacted Xenetic Biosciences's share price.

Xenetic Biosciences share price volatility

Over the last 12 months, Xenetic Biosciences's shares have ranged in value from as little as $2.78 up to $5.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenetic Biosciences's is 2.263. This would suggest that Xenetic Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Xenetic Biosciences overview

Xenetic Biosciences, Inc. , a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies.

Frequently asked questions

What percentage of Xenetic Biosciences is owned by insiders or institutions?
Currently 19.055% of Xenetic Biosciences shares are held by insiders and 2.098% by institutions. How many people work for Xenetic Biosciences?
Latest data suggests 4 work at Xenetic Biosciences. When does the fiscal year end for Xenetic Biosciences?
Xenetic Biosciences's fiscal year ends in December. Where is Xenetic Biosciences based?
Xenetic Biosciences's address is: 945 Concord Street, Framingham, MA, United States, 01701 What is Xenetic Biosciences's ISIN number?
Xenetic Biosciences's international securities identification number is: US9840155033 What is Xenetic Biosciences's CUSIP number?
Xenetic Biosciences's Committee on Uniform Securities Identification Procedures number is: 984015107